Complement Activation for USMLE: Pathways & Deficiencies

High-yield guide to complement activation pathways, C3/C5 convertases, effector functions, deficiency patterns, testing, HAE, and USMLE pitfalls.

Introduction

Complement activation is a plasma-protein cascade that turns pathogen recognition into rapid immune effector function. For USMLE purposes, the entire system can be organized around one core idea: three pathways converge on C3 convertase, then proceed to C5 convertase and the terminal complement pathway.

The classical, lectin, and alternative pathways begin differently, but they share the same major outcomes: C3b-mediated opsonization, C3a/C5a-mediated inflammation, immune-complex clearance, and C5b-9 membrane attack complex lysis. A PubMed-reviewed summary of complement activation highlights these same major pathway mechanisms, including C3/C5 convertase formation, anaphylatoxins, and membrane attack complex activity. (pubmed.ncbi.nlm.nih.gov)

For Step 1, complement is a memorization-heavy topic: know the convertases, products, and deficiency patterns. For Step 2 CK, the same knowledge appears clinically as recurrent meningococcal infection, severe pyogenic infection, lupus-like disease, complement-inhibitor risk, and hereditary angioedema.

Pathophysiology

Three Pathways, One Convergence Point

Complement begins through one of three pathways. The classical pathway links adaptive immunity to complement because it is triggered by antigen-antibody complexes, especially IgM or IgG. The lectin pathway is antibody-independent and begins when mannose-binding lectin or ficolins recognize microbial carbohydrates.

The alternative pathway is the major amplification loop. It begins through spontaneous C3 “tick-over” and is stabilized on microbial surfaces by alternative pathway proteins such as factor B, factor D, and properdin.

Pathway Trigger Early Proteins C3 Convertase C5 Convertase Board Association Classical Antigen-antibody complexes, especially IgM or IgG C1q, C1r, C1s, C4, C2 C4b2a C4b2a3b Adaptive immunity linkage; immune-complex disease; SLE-like disease when early components are deficient Lectin Mannose or microbial carbohydrate patterns MBL/ficolins, MASP, C4, C2 C4b2a C4b2a3b Innate recognition without antibody Alternative Spontaneous C3 tick-over amplified on microbial surfaces C3, factor B, factor D, properdin C3bBb C3bBb3b Major amplification loop; properdin/factor D defects predispose to Neisseria

The highest-yield convertase rule is simple: classical/lectin C3 convertase = C4b2a, while alternative C3 convertase = C3bBb. Adding another C3b converts each C3 convertase into its corresponding C5 convertase.

Effector Products

After C3 convertase formation, complement amplification rapidly generates effector products. C3b coats microbes and immune complexes for phagocytosis, C3a and C5a promote inflammation, and C5b initiates assembly of the terminal C5b-9 membrane attack complex.

Complement Product Main Function High-Yield Clinical Clue C3b Opsonization; immune-complex clearance; formation of C5 convertase C3 deficiency causes severe recurrent infections with encapsulated pyogenic bacteria and immune-complex disease iC3b Opsonin recognized by complement receptors on phagocytes Important for neutrophil/macrophage uptake C3a Anaphylatoxin; mast-cell degranulation; increased vascular permeability Inflammatory amplification C5a Potent neutrophil chemotaxis and activation; anaphylatoxin Often tested as the strongest chemoattractant/anaphylatoxin C5b-9 Membrane attack complex pore formation Terminal complement defects predispose to recurrent Neisseria meningitidis infection

For Step 1, compress the effector functions into three associations: C3b = opsonin, C5a = chemotaxis, and C5b-9 = MAC. If a vignette says “recurrent meningococcal infections,” immediately think of terminal complement deficiency or an alternative pathway amplification defect such as properdin or factor D deficiency.

Regulation of Host-Cell Injury

Complement must be activated on microbes but restrained on host cells. Defects in complement regulation can lead to inappropriate complement consumption, endothelial injury, hemolysis, angioedema, or renal disease.

Regulator Normal Role Defect or Clinical Association C1 esterase inhibitor Inhibits C1r/C1s and MASP; also regulates contact/kallikrein-kinin pathway Hereditary angioedema: bradykinin-mediated swelling, low C4, low C1-INH function Factor H Binds host surfaces and helps factor I degrade C3b Alternative pathway dysregulation; atypical HUS and C3 glomerulopathy patterns Factor I Proteolytically inactivates C3b and C4b with cofactors Excess C3 consumption; recurrent infections and renal disease DAF/CD55 Accelerates decay of C3/C5 convertases Loss with CD59 in PNH due to defective GPI anchors CD59 Blocks C9 polymerization and MAC formation on host cells Loss causes complement-mediated intravascular hemolysis in PNH Properdin Stabilizes alternative pathway C3 convertase X-linked deficiency classically associated with meningococcal infection risk

The PNH association is especially board-friendly: DAF/CD55 and CD59 protect host cells. Loss of GPI-anchored CD55/CD59 allows complement-mediated hemolysis, and C5 blockade reduces terminal complement injury but increases meningococcal risk.

Clinical Presentation

Complement deficiencies are uncommon but highly testable because each affected region of the cascade produces a recognizable infection or immune phenotype. Early classical pathway deficiencies are associated with autoimmune and immune-complex disease, while terminal pathway defects are strongly associated with meningococcal disease. (pubmed.ncbi.nlm.nih.gov)

Deficient Component Typical Clinical Pattern Mechanism Board Pearl C1q, C1r/s, C2, C4 SLE-like autoimmune disease; immune-complex disease; sometimes recurrent sinopulmonary infections Impaired classical pathway activation and immune-complex clearance C2 deficiency is a common inherited complement deficiency tested with lupus-like disease C3 Severe recurrent pyogenic infections; immune-complex disease Loss of central opsonin and convergence point Most severe broad infection risk among complement defects C5-C9 Recurrent Neisseria meningitidis or disseminated gonococcal infection Impaired MAC formation Think “terminal complement = Neisseria” Properdin, factor D Recurrent meningococcal infection Impaired alternative pathway amplification Properdin deficiency is X-linked MBL or MASP Recurrent infections, often more prominent in infancy or with other immune compromise Impaired lectin pathway activation CH50/AH50 may be normal because classical and alternative pathways are intact C1 esterase inhibitor Recurrent nonpitting, nonurticarial angioedema; abdominal pain; laryngeal edema Excess bradykinin generation through contact pathway dysregulation Not histamine-mediated; epinephrine/antihistamines/steroids are not definitive therapy

The highest-yield deficiency map is: C1/C2/C4 → SLE-like disease, C3 → severe pyogenic infections, C5-C9 → recurrent Neisseria, and C1-INH → hereditary angioedema.

Hereditary Angioedema Pattern

Hereditary angioedema due to C1-INH deficiency is usually autosomal dominant and results from deficient or dysfunctional C1 esterase inhibitor. Although C1-INH is a complement regulator, the swelling is primarily mediated by excess bradykinin, which increases vascular permeability through bradykinin B2 receptor signaling. (pubmed.ncbi.nlm.nih.gov)

Clinically, suspect hereditary angioedema when a patient has recurrent swelling without urticaria, episodic severe abdominal pain, a family history, or laryngeal edema. The absence of pruritus and urticaria helps separate bradykinin-mediated disease from histamine-mediated angioedema or anaphylaxis.

Diagnostic Approach

Complement testing starts with functional pathway assays and component levels. CH50 measures total classical pathway hemolytic activity through the terminal pathway; AH50 measures alternative pathway function; C3 and C4 help distinguish consumption from inherited deficiency. A PubMed review of complement investigation emphasizes CH50, C3, and C4 as important screening tools, with further component testing when deficiency is suspected. (pubmed.ncbi.nlm.nih.gov)

Pattern Likely Defect Reason Next Step Low CH50, normal AH50 Early classical pathway deficiency: C1, C2, C4 Classical pathway impaired; alternative pathway intact Measure individual C1q/C2/C4 levels and evaluate for lupus-like disease Normal CH50, low AH50 Alternative pathway defect: factor B, factor D, properdin Alternative amplification impaired Measure alternative pathway components; assess meningococcal history Low CH50 and low AH50 C3 deficiency, terminal C5-C9 deficiency, or complement consumption Shared central/terminal pathway affected or consumed Check C3, C4, terminal components, and activation markers Low C3, normal C4 Alternative pathway activation/consumption C3 consumed without classical C4 consumption Consider C3 glomerulopathy, atypical HUS, factor H/I abnormalities Low C3 and low C4 Classical pathway consumption Immune-complex activation consumes C4 and downstream C3 Consider active SLE, cryoglobulinemia, immune-complex disease Low C4 with normal/low C1-INH function Hereditary or acquired C1-INH deficiency Unregulated classical/contact pathway activation Measure C1-INH antigen, C1-INH function, and C1q if acquired disease suspected

For Step 1, remember: CH50 screens classical + terminal, while AH50 screens alternative + terminal. If both are low, the defect is central/terminal or there is active consumption.

For Step 2 CK, avoid diagnosing inherited complement deficiency from one low complement value during acute infection or an autoimmune flare. Repeat testing and order component-specific assays when the clinical pattern suggests an inherited defect.

Management & Prevention

Management depends on the clinical syndrome. For recurrent meningococcal disease or infection despite appropriate vaccination, evaluate for complement deficiency or complement inhibitor exposure. CDC/ACIP guidance includes persistent complement component deficiency and complement inhibitor use among high-risk groups for MenACWY and MenB vaccination. (cdc.gov)

Patients receiving complement inhibitors, especially C5 inhibitors such as eculizumab or ravulizumab, remain at markedly increased risk for meningococcal disease even after vaccination. CDC recommends MenACWY and MenB vaccination and a high index of suspicion for meningococcal symptoms in patients receiving complement inhibitor therapy. (cdc.gov)

For prevention during complement inhibitor therapy, CDC guidance notes that MenACWY boosters are given every 5 years for the duration of therapy. MenB boosters are given 1 year after series completion and then every 2–3 years while risk persists. (cdc.gov)

Hereditary angioedema management targets C1-INH replacement, bradykinin B2 receptor blockade, or kallikrein inhibition. Acute attack options include plasma-derived or recombinant C1-INH, icatibant, and ecallantide; long-term prophylaxis can include C1-INH replacement or kallikrein-directed therapy such as lanadelumab or berotralstat. (pubmed.ncbi.nlm.nih.gov)

In a patient with airway symptoms from suspected hereditary angioedema, airway protection comes first. Then give targeted on-demand therapy rather than relying on antihistamines or steroids, because the disease is bradykinin-mediated rather than mast-cell mediated.

High-Yield Differentials & Pitfalls

Complement vignettes often look similar at first glance: infection, swelling, low complement levels, or autoimmune disease. The key is to match the syndrome to the specific part of the cascade.

Presentation Most Likely Complement Issue Common Pitfall How to Avoid It Young patient with lupus-like disease Early classical pathway deficiency: C1, C2, C4 Assuming all low complement states are acquired SLE activity Look for early onset and recurrent immune-complex disease Severe recurrent pyogenic infections C3 deficiency Jumping to terminal complement deficiency C3 is central for opsonization and immune-complex clearance Recurrent meningococcal infection C5-C9, properdin, or factor D deficiency Forgetting alternative pathway amplification defects Terminal MAC and alternative pathway amplification both protect against Neisseria Nonurticarial swelling with abdominal pain C1-INH deficiency Treating as histamine-mediated allergy only Low C4 and low C1-INH function point to bradykinin disease PNH with hemolysis Loss of CD55/CD59 Thinking MAC only attacks microbes Host cells require complement regulators to avoid injury Low complement during infection or flare Complement consumption Diagnosing inherited deficiency from one test Repeat testing and order component-specific assays when clinically indicated

A classic exam trap is confusing C3a and C5a. Both are anaphylatoxins, but C5a is the strongest neutrophil chemoattractant and activator in the high-yield board framework.

Another common pitfall is assuming meningococcal vaccination eliminates risk in patients receiving C5 inhibitors. CDC specifically emphasizes that substantial risk remains and that clinicians should maintain high suspicion for meningococcal symptoms in complement-inhibitor recipients. (cdc.gov)

Exam Vignette

A 19-year-old man is evaluated after his second episode of meningococcal meningitis. He completed routine childhood immunizations and has no history of recurrent viral or fungal infections. Laboratory screening shows abnormal terminal complement pathway function.

Most likely category: Terminal complement deficiency, such as C5-C9 deficiency. Why Neisseria? The terminal pathway forms the C5b-9 membrane attack complex, which is especially associated with defense against Neisseria species. What else could be tested? Properdin or factor D deficiency can also predispose to recurrent meningococcal disease through impaired alternative pathway amplification. Board shortcut: “Recurrent meningococcal infection” should trigger terminal complement or alternative amplification defect. Prevention angle: Patients with persistent complement component deficiency are a high-risk group for meningococcal vaccination recommendations. (cdc.gov)

Key Takeaways

Complement activation has three pathways: classical, lectin, and alternative. All three pathways converge on C3 convertase, then form C5 convertase, then proceed to terminal complement. Classical/lectin C3 convertase = C4b2a. Alternative C3 convertase = C3bBb. Adding one more C3b creates the corresponding C5 convertase. C3b is the major opsonin and supports immune-complex clearance. C5a is the strongest high-yield chemoattractant/anaphylatoxin. C5b-9 is the membrane attack complex and is linked to recurrent Neisseria infection. C1/C2/C4 deficiency is associated with SLE-like immune-complex disease. C3 deficiency causes severe recurrent pyogenic infections and immune-complex disease. C5-C9 deficiency causes recurrent Neisseria infections. C1-INH deficiency causes hereditary angioedema, a bradykinin-mediated disorder. CH50 screens classical plus terminal pathway function; AH50 screens alternative plus terminal pathway function.

Keep Learning

When reviewing complement, do not start by memorizing every protein in isolation. Instead, build from the convergence point: pathway trigger → C3 convertase → C5 convertase → effector function → deficiency phenotype.

For Step 1, drill the convertases and the classic deficiency map until they are automatic. For Step 2 CK, connect those mechanisms to clinical decisions: when to order CH50/AH50, when to suspect hereditary angioedema, and when meningococcal risk remains high despite vaccination in patients receiving complement inhibitors. (cdc.gov)